Cargando…

Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ in efficacy, side effects, dosing frequency, and device-related attributes. This study assessed the relative importance of treatment-related attributes in influencing preferences for GLP-1RAs among injection-naïve patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Lei, Chen, Stephanie, Flood, Emuella, Shaunik, Alka, Romero, Beverly, de la Cruz, Marie, Alvarez, Cynthia, Grandy, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380493/ https://www.ncbi.nlm.nih.gov/pubmed/28155131 http://dx.doi.org/10.1007/s13300-017-0230-2

Ejemplares similares

Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
por: Qin, Lei, et al.
Publicado: (2017)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Kayaniyil, Sheena, et al.
Publicado: (2016)

Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
por: Gelhorn, Heather L, et al.
Publicado: (2016)

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis
por: Rayner, Christopher K., et al.
Publicado: (2020)

The patient journey to diagnosis and treatment of congenital sucrase-isomaltase deficiency
por: Smith, Heather, et al.
Publicado: (2021)

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
por: Hirji, Ishan, et al.
Publicado: (2014)

A Conceptual Model of Angelman Syndrome and Review of Relevant Clinical Outcomes Assessments (COAs)
por: Grieco, Joseph C., et al.
Publicado: (2018)

The time‐varying cardiovascular benefits of glucagon‐like peptide‐1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials
por: Deo, Salil V., et al.
Publicado: (2022)

Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication
por: DiBonaventura, Marco daCosta, et al.
Publicado: (2010)

Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries
por: Flood, Emuella M, et al.
Publicado: (2006)

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
por: Gelhorn, Heather L, et al.
Publicado: (2015)

Development of the pediatric daily ulcerative colitis signs and symptoms scale (DUCS): qualitative research findings
por: Flood, Emuella, et al.
Publicado: (2017)

Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Banjara, Bidur, et al.
Publicado: (2022)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Preferences for Attention-Deficit/Hyperactivity Disorder (ADHD) Non-Stimulant Treatment Characteristics Among Children and Adolescents With ADHD and Their Caregivers
por: Flood, Emuella, et al.
Publicado: (2016)

Glucagon-Like Peptide-1 Agonist Exendin-4 Facilitates the Extinction of Cocaine-Induced Condition Place Preference
por: Zhu, Changliang, et al.
Publicado: (2021)

Glucagon changes substrate preference in gluconeogenesis
por: Xu, Huiting, et al.
Publicado: (2022)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
por: Di Loreto, Chiara, et al.
Publicado: (2022)

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
por: Pelle, Maria Chiara, et al.
Publicado: (2023)

Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
por: Di Loreto, Chiara, et al.
Publicado: (2022)

Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice
por: Zhu, Changliang, et al.
Publicado: (2022)

Preference of acromegaly patients for treatment attributes in Spain
por: Fajardo, Carmen, et al.
Publicado: (2023)

The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
por: Brice, Kira R., et al.
Publicado: (2011)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”
por: Brooks, Anne B., et al.
Publicado: (2020)

Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study
por: Janssens, Rosanne, et al.
Publicado: (2021)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2014)

SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study
por: Graybill, Sky
Publicado: (2019)

PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE
por: Poulos, Christine, et al.
Publicado: (2018)

A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
por: Pan, Changyu, et al.
Publicado: (2016)

Naïve Chicks Prefer Hollow Objects
por: Versace, Elisabetta, et al.
Publicado: (2016)

Real-World Patient Experience on the Path to Diagnosis of Ankylosing Spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q1mbk3n39ai4irro3n2ebag365